Glucagon Like Peptide 2 Receptor (GLP2R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Glucagon Like Peptide 2 Receptor (GLP2R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Glucagon Like Peptide 2 Receptor - Drugs In Development, 2022'; Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

The report 'Glucagon Like Peptide 2 Receptor - Drugs In Development, 2022' outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 1, 2, 1, 8, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Other Diseases and Undisclosed which include indications Short Bowel Syndrome, Graft Versus Host Disease (GVHD), Crohn's Disease (Regional Enteritis), Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Non-Alcoholic Steatohepatitis (NASH), Obesity, Osteoporosis, Unspecified and Unspecified Metabolic Disorders.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
  • The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Glucagon Like Peptide 2 Receptor (GLP2R) – Overview
Glucagon Like Peptide 2 Receptor (GLP2R) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucagon Like Peptide 2 Receptor (GLP2R) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucagon Like Peptide 2 Receptor (GLP2R) – Companies Involved in Therapeutics Development
9 Meters Biopharma Inc
Amogen Pharma Pvt Ltd
Applied Molecular Transport Inc
Bainan Biotech ApS
Entera Bio Ltd
Hanmi Pharmaceuticals Co Ltd
Huons Global Co Ltd
OPKO Health Inc
Peg-Bio BioPharma Co Ltd
PhaseBio Pharmaceuticals Inc
Sosei Group Corp
Takeda Pharmaceutical Co Ltd
Tasly Pharmaceutical Group Co Ltd
VectivBio Holding AG
Zealand Pharma AS
Glucagon Like Peptide 2 Receptor (GLP2R) – Drug Profiles
apraglutide – Drug Profile
dapiglutide – Drug Profile
Drugs to Agonize GIP and GLP-2 for Osteoporosis – Drug Profile
glepaglutide – Drug Profile
GLP-2 – Drug Profile
GLP2-ELP – Drug Profile
GXG-8 – Drug Profile
HL-06 – Drug Profile
HM-15912 – Drug Profile
HTL-023 – Drug Profile
MOD-1501 – Drug Profile
NB-1002 – Drug Profile
teduglutide – Drug Profile
Glucagon Like Peptide 2 Receptor (GLP2R) – Dormant Products
Glucagon Like Peptide 2 Receptor (GLP2R) – Discontinued Products
Glucagon Like Peptide 2 Receptor (GLP2R) – Product Development Milestones
Featured News & Press Releases
Jun 06, 2022: Zealand Pharma presents data from phase 1 trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and announces Dapiglutide to move into phase 2 trial for obesity
Jun 02, 2022: VectivBio announces first two patients dosed in phase 2 STARGAZE study of apraglutide for the treatment of acute graft-versus-host disease
Jun 01, 2022: NICE recommends Revestive (teduglutide) for the treatment of adults and children living with Short Bowel Syndrome (SBS)
Mar 29, 2022: VectivBio presents new clinical data supporting apraglutide for treatment of short bowel syndrome with intestinal failure (SBS-IF) patients who have renal dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition Conference
Mar 23, 2022: VectivBio presents preclinical data supporting Apraglutide for treatment of Acute Graft-Versus-Host Disease at the 48th annual meeting of the European Society for Blood and Marrow Transplantation
Jan 20, 2022: Zealand Pharma completes enrollment in EASE-SBS 1 phase 3 trial assessing Glepaglutide in patients with short bowel syndrome
Dec 16, 2021: Zealand Pharma announces enrollment of last patient needed for interim analysis of EASE-SBS 1 phase 3 trial assessing Glepaglutide in patients with short bowel syndrome
Nov 22, 2021: Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide
Oct 20, 2021: VectivBio announces successful opening of US IND for Apraglutide for acute graft-versus-host disease
Sep 16, 2021: VectivBio announces upcoming investor events
Sep 13, 2021: Providing innovative treatment options for patients with intractable rare disease short bowel syndrome
Sep 09, 2021: Zealand Pharma presents data at 2021 ESPEN Virtual Congress Demonstrating Dose-dependent Effects of Glepaglutide in both small and large intestines of animal models – in contrast to short-acting GLP-2
Aug 19, 2021: Zealand Pharma announces first patient dosed in EASE-SBS 4 phase 3b trial assessing glepaglutide in patients with short bowel syndrome
Jun 29, 2021: Zealand Pharma to present data on glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)
Jun 24, 2021: VectivBio receives FDA Orphan Drug Designation for apraglutide for acute graft-versus-host disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development by Stage of Development, 2022
Table 2: Number of Products under Development by Therapy Areas, 2022
Table 3: Number of Products under Development by Indication, 2022
Table 4: Number of Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Number of Products under Investigation by Universities/Institutes, 2022
Table 8: Products under Investigation by Universities/Institutes, 2022
Table 9: Number of Products by Stage and Mechanism of Actions, 2022
Table 10: Number of Products by Stage and Route of Administration, 2022
Table 11: Number of Products by Stage and Molecule Type, 2022
Table 12: Pipeline by 9 Meters Biopharma Inc, 2022
Table 13: Pipeline by Amogen Pharma Pvt Ltd, 2022
Table 14: Pipeline by Applied Molecular Transport Inc, 2022
Table 15: Pipeline by Bainan Biotech ApS, 2022
Table 16: Pipeline by Entera Bio Ltd, 2022
Table 17: Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Table 18: Pipeline by Huons Global Co Ltd, 2022
Table 19: Pipeline by OPKO Health Inc, 2022
Table 20: Pipeline by Peg-Bio BioPharma Co Ltd, 2022
Table 21: Pipeline by PhaseBio Pharmaceuticals Inc, 2022
Table 22: Pipeline by Sosei Group Corp, 2022
Table 23: Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Table 24: Pipeline by Tasly Pharmaceutical Group Co Ltd, 2022
Table 25: Pipeline by VectivBio Holding AG, 2022
Table 26: Pipeline by Zealand Pharma AS, 2022
Table 27: Dormant Products, 2022
Table 28: Dormant Products, 2022 (Contd..1)
Table 29: Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development by Stage of Development, 2022
Figure 2: Number of Products under Development by Therapy Areas, 2022
Figure 3: Number of Products under Development by Top 10 Indications, 2022
Figure 4: Number of Products by Stage and Mechanism of Actions, 2022
Figure 5: Number of Products by Routes of Administration, 2022
Figure 6: Number of Products by Stage and Routes of Administration, 2022
Figure 7: Number of Products by Molecule Types, 2022
Figure 8: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings